Marinus Pharmaceuticals, Inc. (MRNS)
Feb 11, 2025 - MRNS was delisted (reason: acquired by Immedica)
0.550
+0.001 (0.09%)
Inactive · Last trade price
on Feb 11, 2025
Marinus Pharmaceuticals Stock Forecast
MRNS's stock price has decreased by -94.55% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Marinus Pharmaceuticals stock had an average target of 4.28, with a low estimate of 0.50 and a high estimate of 10.
Analyst Consensus: Buy
* Price targets were last updated on Nov 14, 2024.
Analyst Ratings
The average analyst rating for Marinus Pharmaceuticals stock from 12 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 7 | 7 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $4 | Buy | Reiterates | $4 | +627.27% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $2 | Hold | Reiterates | $2 | +263.64% | Nov 14, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $3 | Strong Buy | Maintains | $3 | +445.45% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 25, 2024 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 25, 2024 |
Financial Forecast
Revenue This Year
35.63M
from 30.99M
Increased by 14.97%
Revenue Next Year
56.17M
from 35.63M
Increased by 57.65%
EPS This Year
-2.11
from -2.63
EPS Next Year
-0.50
from -2.11
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 39.7M | 76.3M | 73.9M | |||
| Avg | 35.6M | 56.2M | 62.5M | |||
| Low | 33.1M | 43.5M | 53.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 28.1% | 114.2% | 31.6% | |||
| Avg | 15.0% | 57.7% | 11.3% | |||
| Low | 6.7% | 22.1% | -4.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.08 | -0.26 | -0.24 | |||
| Avg | -2.11 | -0.50 | -0.30 | |||
| Low | -2.12 | -0.98 | -0.38 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.